Publicação
Spectrum of non-nucleoside reverse transcriptase inhibitor-associated drug resistance mutations in persons living with HIV-1 receiving rilpivirine
| datacite.subject.fos | Ciências Médicas::Ciências da Saúde | |
| datacite.subject.sdg | 03:Saúde de Qualidade | |
| dc.contributor.author | Nagarajan, Pavithra | |
| dc.contributor.author | Zhou, Jinru | |
| dc.contributor.author | Teodoro, Giulia Di | |
| dc.contributor.author | Incardona, Francesca | |
| dc.contributor.author | Seguin-Devaux, Carole | |
| dc.contributor.author | Kaiser, Rolf | |
| dc.contributor.author | Abecasis, Ana B. | |
| dc.contributor.author | Gomes, Perpétua | |
| dc.contributor.author | Tao, Kaiming | |
| dc.contributor.author | Zazzi, Maurizio | |
| dc.contributor.author | Shafer, Robert W. | |
| dc.contributor.author | on behalf of the EuResist Network | |
| dc.date.accessioned | 2026-04-23T13:51:53Z | |
| dc.date.available | 2026-04-23T13:51:53Z | |
| dc.date.issued | 2024-11 | |
| dc.description.abstract | Introduction: Few data are currently available on the nonnucleoside reverse transcriptase (RT) inhibitors (NNRTI) resistance mutations selected in persons living with HIV-1 (PLWH) who develop virological failure while receiving rilpivirine (RPV). Methods: We analyzed pooled HIV-1 RT genotypic data from 280 PLWH in the multicenter EuResist database and 115 PLWH in the Stanford HIV Drug Resistance Database (HIVDB) who received RPV as their only NNRTI. Results: Among the 395 PLWH receiving RPV, 180 (45.6%) had one or more NNRTI-associated DRMs. Overall, 44 NNRTI-associated DRMs were identified, including 26 that occurred in two or more PLWHs. Seven mutations had a prevalence ≥10% among the 180 PLWH with one or more NNRTI-associated DRM: E138K (32.2%), V90I (25.0%), K101E (17.8%), Y181C (17.2%), E138A (13.9%), H221Y (12.2%), and K103N (10.6%). Y181C was significantly more likely to co-occur with K101E, V179F, H221Y, and M230L. Ten novel non-polymorphic mutations at known NNRTI-associated mutation positions were also identified, usually in just one PLWH: L100F, V108A, T139I, P225S, M230V, Y232C, and T240A/I/M/S. Conclusions: Our analysis extends the spectrum of mutations emerging in PLWH receiving RPV. Additional phenotypic characterization of RPV-selected mutations is necessary to better understand their biological and possible clinical significance. | eng |
| dc.identifier.citation | Nagarajan P, Zhou J, Di Teodoro G, Incardona F, Seguin-Devaux C, Kaiser R, Abecasis AB, Gomes P, Tao K, Zazzi M, et al. Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine. Viruses. 2024; 16(11):1715. https://doi.org/10.3390/v16111715 | |
| dc.identifier.doi | 10.3390/v16111715 | |
| dc.identifier.issn | 1999-4915 | |
| dc.identifier.uri | http://hdl.handle.net/10400.26/62837 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.publisher | MDPI | |
| dc.relation.hasversion | https://doi.org/10.3390/v16111715 | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | rilpivirine | |
| dc.subject | HIV-1 drug resistance | |
| dc.subject | non-nucleoside reverse transcriptase inhibitors | |
| dc.title | Spectrum of non-nucleoside reverse transcriptase inhibitor-associated drug resistance mutations in persons living with HIV-1 receiving rilpivirine | eng |
| dc.type | contribution to journal | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 11 | |
| oaire.citation.startPage | 1715 | |
| oaire.citation.title | Viruses | |
| oaire.citation.volume | 16 | |
| oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 |